<DOC>
	<DOCNO>NCT02739360</DOCNO>
	<brief_summary>This study provide idelalisib participant receive GS-9820 Gilead-sponsored Study GS-US-315-0102 time study closure .</brief_summary>
	<brief_title>Roll Over Study Provide Idelalisib Participants Previously Treated With Investigational PI3KÎ´ Inhibitor , GS-9820</brief_title>
	<detailed_description />
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Receiving GS9820 Study GSUS3150102 objective evidence clinical benefit Evidence personally sign informed consent Known hypersensitivity intolerance active substance excipients formulation idelalisib Toxicities would preclude initiate therapy idelalisib prior enrollment Concurrent participation another therapeutic clinical trial Ongoing infection , treatment , prophylaxis cytomegalovirus ( CMV ) within past 28 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>